Epigenomics

A new study in Cancer Medicine reports on micro-simulation model results indicating that Epi proColon provides clinically meaningful reductions in the incidence and mortality of CRC comparable to currently recommended methods. Read the full results @ https://onlinelibrary.wiley.com/doi/10.1002/cam4.2735

Micro-simulation model results showed that Epi proColon, Epigenomics’ colorectal cancer (CRC) screening test provides clinically meaningful reductions in the incidence and mortality of CRC comparable to currently recommended methods

Microsimulation model is the first to incorporate colorectal cancer screening methods' adherence rates. Epi proColon, FDA-approved blood test, demonstrated high clinical effectiveness for colorectal cancer screening detection.

Epigenomics is honored to receive the 2019 Top 10 In-Vitro Diagnostic Award for developing innovative blood-based cancer screening products like Epi proColon, Epi proLung, and HCCBloodTest.

Methylated Septin 9 (Epi proColon blood test) has been studied in Lynch Syndrome patients who are avoiding colonoscopy.

Epi proColon receives 2019 Excellence in Molecular Diagnostics award for innovative blood-based solution to address colorectal cancer screening. This disruptive technology is intended for patients who are not up-to-date on the colorectal cancer screening. Get Screened!!!

The Chicago CLMA Chapter was recognized at the CLMA KnowledgeLab Conference in Houston.